Hormone Responses During Hypoglycemia and the Accuracy of Continuous Glucose Monitors
NCT ID: NCT00607139
Last Updated: 2016-09-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
28 participants
Study Classification
OBSERVATIONAL
Study Start Date
2006-12-31
Study Completion Date
2007-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective of this study will be to compare the glucose level at which counter-regulatory hormone responses occur during hypoglycemia in young children with diabetes, with the glucose level counter regulatory hormone responses that occur in older children with diabetes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DM
NCT00760526
Diabetes Mellitus, Type 1
COMPLETED
PHASE3
Assessing Continuous Glucose Monitors in Healthy Children
NCT00069602
Diabetes Mellitus
COMPLETED
PHASE4
Continuous Glucose Monitors for Children With Diabetes Mellitus
NCT00069537
Diabetes Mellitus, Insulin-Dependent
COMPLETED
PHASE4
Pilot Study of the Navigator Continuous Glucose Monitor
NCT00166673
Diabetes Mellitus, Insulin-Dependent
COMPLETED
PHASE2/PHASE3
Impact of Hypoglycemia Unawareness on Brain Metabolism Cognition in T1DM
NCT00575783
Type 1 Diabetes
Hypoglycemia
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The present study is being undertaken to compare counterregulatory hormone responses to a mild and gradual reduction in plasma glucose in young children with T1DM versus responses in adolescents. The studies will be performed under the close supervision of the professional staff of each DirecNet center and frequent bedside monitoring of plasma glucose concentrations will ensure that clinically significant hypoglycemia is prevented from developing. All subjects will be admitted to the CRC and have an IV line for blood sampling inserted on the evening prior to study to reduce stress on the morning of the study. The study procedure will be simplified and made less invasive in comparison to a clamp or standard insulin infusion study (i.e. only the one IV for blood sampling will be needed) by limiting enrollment to insulin pump-treated subjects who will have their basal rates modestly increased to produce the hypoglycemic stimulus. Monsod and colleagues used the same procedure of increasing the basal insulin infusion dose to induce a gradual fall in plasma glucose in youth with type 1 diabetes in a study that compared the ability of injections of glucagon and epinephrine to treat mild hypoglycemia. It is particularly important to note that once the blood glucose level falls below 60 mg/dl, a blood sample will be obtained and hypoglycemia will then be immediately corrected by intravenous administration of exogenous glucose. In our recent DirecNet study, \~25% of children and adolescents had plasma glucose levels below 60 mg/dl during a typical night and this rose to \~50% of subjects when there was antecedent exercise in the late afternoon. Moreover, the frequency of mild as well as severe hypoglycemia is substantially higher in pre-school children than in children and adolescents. This safe and rigorously designed study will provide important new information regarding the role of inadequate counter-regulation on the increased risk of hypoglycemia in very young children with T1DM.
Real-time continuous glucose sensing systems offer the potential to markedly lower the risk of hypoglycemia in youth with T1DM. However, the DirecNet inpatient accuracy study demonstrated that the first generation of these devices was inaccurate when blood glucose was lowered to less than 70 mg/dl. In that study, children with T1DM between 3-17 years of age were admitted to the CRC for approximately 26 hours during which they wore 1-2 Medtronic MiniMed CGMS and 1-2 Cygnus GlucoWatch G2 Biographer continuous glucose monitors. In every subject in that study, blood samples were obtained every 30-60 minutes from an indwelling intravenous catheter for measurement of reference plasma glucose levels in the DirecNet Central Laboratory. The Guardian-RT continuous glucose monitoring systems is a real-time continuous glucose monitor that has considerable promise for use in children with diabetes. Therefore, a secondary aim of this study is to obtain very important data regarding the accuracy of this system during hypoglycemia in young children, as well as adolescents.
The Guardian-RT has been approved by the FDA for detecting trends and tracking patterns in adults (18 and older) and are indicated for adjunctive rather than replacement of standard home glucose monitoring devices. The sensor has been approved by the FDA for use for up to 72 hours but can function for a longer period of time.
The primary objective of this study will be to compare the glucose level at which counter-regulatory hormone responses occur during hypoglycemia in young children with diabetes, with the glucose level counter regulatory hormone responses that occur in older children with diabetes. We hypothesize that the children in the younger age group will not have a counterregulatory response until a lower glucose level is reached compared with children in the older age group.
Secondary objectives will be:
1. To assess signs and symptoms at different glucose levels of hypoglycemia in younger children and compare those with the older children. Furthermore, symptoms will be compared to counter regulatory hormone levels in the two age groups. Symptoms will be assessed using physiologic data and using an age-appropriate questionnaire that would be completed during the test by the subject (where appropriate) and by a parent.
2. To assess whether there is a difference in counter-regulatory hormone response in each age group, among those who had at least 2-3 episodes of hypoglycemia per day or night prior to the study compared with those who had an occasional or no episodes of hypoglycemia prior to the test. Subjects will wear a Guardian RT for 6 days (+1 day) prior to the test to assess episodes of hypoglycemia.
3. To examine the accuracy of the Guardian-RT during hypoglycemia in children with type 1 diabetes.
Beginning the Study
When a child enters the study, the following will be done:
1. Informed consent is obtained from eligible subjects (age 3 to \<7 or 12 to \<18 years, T1D for \>1 year, insulin pump being used).
2. On the day of enrollment a hemoglobin A1c is obtained and instructions are given for use of the Guardian RT. The study personnel will supervise the subject or parent inserting the sensor in the clinic. The subject will be instructed to complete at least four glucose measurements a day using the study HGM. Instructions will also be given for response to Guardian RT alarms prior to the CRC admission.
3. The subject will return for an 18-hour overnight CRC admission approximately 6 days (+ 1 day) after the enrollment visit.
* Subjects will continue using the Guardian RT sensor inserted prior to the admission.
* For subjects of sufficient size to accommodate additional devices, a second Guardian-RT sensor will be inserted. An intravenous catheter will be inserted for reference measurements (glucose, epinephrine, norepinephrine, cortisol, glucagon and GH), which will be drawn during the subcutaneous insulin infusion test the following morning to send to a central laboratory.
* For subjects of sufficient weight (subjects \>14.9kg at reinfusion centers and \>26.3kg at discard centers) to accommodate the volume of blood required, blood glucose measurements will be made every 30 minutes during the admission to allow for assessment of the accuracy of the Guardian-RT.
* For subjects of sufficient weight to accommodate the volume of blood required, blood glucose measurements will be made every 15 minutes for two hours after dinner. This will allow for assessment of the accuracy of the Guardian-RT in detecting change during a period of rising blood glucose.
* At approximately 8:00 a.m. the subcutaneous insulin infusion test will start.
* Prior to starting the test, a HypoMon® may be placed around the subject's chest using an adjustable strap.
* The glucose concentration as measured by the study HGM must be \>110 mg/dL to start the test.
* At the start of the test, the basal insulin rate will be increased by approximately 25-50% to provide a gradual decline in blood glucose. A small priming bolus dose of insulin equal to approximately one hour of the subject's usual basal dose may also be given at the discretion of the investigator in addition to the 25-50% increase in the basal insulin.
* The basal insulin rate may be increased an additional amount and additional bolus insulin doses may be given at the discretion of the investigator in order to get a gradual decline in the glucose concentration.
* Blood samples will be collected for the laboratory and glucose will be checked with the study HGM with venous blood every 15 minutes until the glucose level reaches 100 mg/dL. Thereafter, the study HGM will be used to check the glucose levels with venous blood every 5-10 minutes depending on the rate of fall of the glucose level until the end of the study.
* Blood samples will be collected for laboratory determination of hormone concentrations at baseline (before increasing the insulin infusion) and when the glucose levels are \<90, \<80, \<70, and \<60 mg/dL.
* Subjects (or parent if appropriate) will be asked questions regarding symptoms of hypoglycemia each time the glucose level is checked with the study HGM.
* Once the endpoint is reached (the first time the glucose is \<60 mg/dL using the study HGM), the basal rate will be returned to normal, the subjects will be treated with intravenous glucose and breakfast will be provided.
4. Prior to discharge, the sensors will be removed and downloaded and the subject's insulin pump will be downloaded if possible
About 6 days (+1 day) following the enrollment visit, subjects will have an inpatient CRC admission of approximately 18 hours. Subjects will be admitted at approximately 3:00 PM to allow sufficient time to calibrate the sensors before dinner is provided.
* Areas where a Guardian RT sensor was worn during the first week will be assessed by study personnel for any skin irritation.
* The Guardian RT, HGM, and pump data from the previous week will be reviewed and changes will be made to diabetes management as needed.
* Subjects will continue using the Guardian RT sensor last inserted at home. If the sensor is not functioning properly, a new sensor will be inserted.
* For subjects of sufficient size, an additional Guardian-RT sensor will be inserted and calibrated approximately two hours later. An intravenous catheter will be inserted in an arm vein for collection of blood samples during the admission. The area where the catheter will be inserted may be numbed with Elamax or EMLA cream prior to catheter insertion.
Once the study endpoint is reached (the first time the glucose is \<60 mg/dL using the study HGM), the basal rate will be returned to normal and the subjects will be treated with intravenous glucose. An additional blood sample will be collected for laboratory determination of glucose and hormone concentrations 15 minutes following the treatment with intravenous glucose. Subjects will then be given breakfast and discharged. Prior to discharge, the sensor(s) will be removed and downloaded. The subject's insulin pump will be downloaded if possible.
Real-time continuous glucose sensing systems offer the potential to markedly lower the risk of hypoglycemia in youth with T1DM. However, the DirecNet inpatient accuracy study demonstrated that the first generation of these devices was inaccurate when blood glucose was lowered to less than 70 mg/dl. In that study, children with T1DM between 3-17 years of age were admitted to the CRC for approximately 26 hours during which they wore 1-2 Medtronic MiniMed CGMS and 1-2 Cygnus GlucoWatch G2 Biographer continuous glucose monitors. In every subject in that study, blood samples were obtained every 30-60 minutes from an indwelling intravenous catheter for measurement of reference plasma glucose levels in the DirecNet Central Laboratory. The Guardian-RT continuous glucose monitoring systems is a real-time continuous glucose monitor that has considerable promise for use in children with diabetes. Therefore, a secondary aim of this study is to obtain very important data regarding the accuracy of this system during hypoglycemia in young children, as well as adolescents.
The Guardian-RT has been approved by the FDA for detecting trends and tracking patterns in adults (18 and older) and are indicated for adjunctive rather than replacement of standard home glucose monitoring devices. The sensor has been approved by the FDA for use for up to 72 hours but can function for a longer period of time.
The primary objective of this study will be to compare the glucose level at which counter-regulatory hormone responses occur during hypoglycemia in young children with diabetes, with the glucose level counter regulatory hormone responses that occur in older children with diabetes. We hypothesize that the children in the younger age group will not have a counterregulatory response until a lower glucose level is reached compared with children in the older age group.
Secondary objectives will be:
1. To assess signs and symptoms at different glucose levels of hypoglycemia in younger children and compare those with the older children. Furthermore, symptoms will be compared to counter regulatory hormone levels in the two age groups. Symptoms will be assessed using physiologic data and using an age-appropriate questionnaire that would be completed during the test by the subject (where appropriate) and by a parent.
2. To assess whether there is a difference in counter-regulatory hormone response in each age group, among those who had at least 2-3 episodes of hypoglycemia per day or night prior to the study compared with those who had an occasional or no episodes of hypoglycemia prior to the test. Subjects will wear a Guardian RT for 6 days (+1 day) prior to the test to assess episodes of hypoglycemia.
3. To examine the accuracy of the Guardian-RT during hypoglycemia in children with type 1 diabetes.
Beginning the Study
When a child enters the study, the following will be done:
1. Informed consent is obtained from eligible subjects (age 3 to \<7 or 12 to \<18 years, T1D for \>1 year, insulin pump being used).
2. On the day of enrollment a hemoglobin A1c is obtained and instructions are given for use of the Guardian RT. The study personnel will supervise the subject or parent inserting the sensor in the clinic. The subject will be instructed to complete at least four glucose measurements a day using the study HGM. Instructions will also be given for response to Guardian RT alarms prior to the CRC admission.
3. The subject will return for an 18-hour overnight CRC admission approximately 6 days (+ 1 day) after the enrollment visit.
* Subjects will continue using the Guardian RT sensor inserted prior to the admission.
* For subjects of sufficient size to accommodate additional devices, a second Guardian-RT sensor will be inserted. An intravenous catheter will be inserted for reference measurements (glucose, epinephrine, norepinephrine, cortisol, glucagon and GH), which will be drawn during the subcutaneous insulin infusion test the following morning to send to a central laboratory.
* For subjects of sufficient weight (subjects \>14.9kg at reinfusion centers and \>26.3kg at discard centers) to accommodate the volume of blood required, blood glucose measurements will be made every 30 minutes during the admission to allow for assessment of the accuracy of the Guardian-RT.
* For subjects of sufficient weight to accommodate the volume of blood required, blood glucose measurements will be made every 15 minutes for two hours after dinner. This will allow for assessment of the accuracy of the Guardian-RT in detecting change during a period of rising blood glucose.
* At approximately 8:00 a.m. the subcutaneous insulin infusion test will start.
* Prior to starting the test, a HypoMon® may be placed around the subject's chest using an adjustable strap.
* The glucose concentration as measured by the study HGM must be \>110 mg/dL to start the test.
* At the start of the test, the basal insulin rate will be increased by approximately 25-50% to provide a gradual decline in blood glucose. A small priming bolus dose of insulin equal to approximately one hour of the subject's usual basal dose may also be given at the discretion of the investigator in addition to the 25-50% increase in the basal insulin.
* The basal insulin rate may be increased an additional amount and additional bolus insulin doses may be given at the discretion of the investigator in order to get a gradual decline in the glucose concentration.
* Blood samples will be collected for the laboratory and glucose will be checked with the study HGM with venous blood every 15 minutes until the glucose level reaches 100 mg/dL. Thereafter, the study HGM will be used to check the glucose levels with venous blood every 5-10 minutes depending on the rate of fall of the glucose level until the end of the study.
* Blood samples will be collected for laboratory determination of hormone concentrations at baseline (before increasing the insulin infusion) and when the glucose levels are \<90, \<80, \<70, and \<60 mg/dL.
* Subjects (or parent if appropriate) will be asked questions regarding symptoms of hypoglycemia each time the glucose level is checked with the study HGM.
* Once the endpoint is reached (the first time the glucose is \<60 mg/dL using the study HGM), the basal rate will be returned to normal, the subjects will be treated with intravenous glucose and breakfast will be provided.
4. Prior to discharge, the sensors will be removed and downloaded and the subject's insulin pump will be downloaded if possible
About 6 days (+1 day) following the enrollment visit, subjects will have an inpatient CRC admission of approximately 18 hours. Subjects will be admitted at approximately 3:00 PM to allow sufficient time to calibrate the sensors before dinner is provided.
* Areas where a Guardian RT sensor was worn during the first week will be assessed by study personnel for any skin irritation.
* The Guardian RT, HGM, and pump data from the previous week will be reviewed and changes will be made to diabetes management as needed.
* Subjects will continue using the Guardian RT sensor last inserted at home. If the sensor is not functioning properly, a new sensor will be inserted.
* For subjects of sufficient size, an additional Guardian-RT sensor will be inserted and calibrated approximately two hours later. An intravenous catheter will be inserted in an arm vein for collection of blood samples during the admission. The area where the catheter will be inserted may be numbed with Elamax or EMLA cream prior to catheter insertion.
Once the study endpoint is reached (the first time the glucose is \<60 mg/dL using the study HGM), the basal rate will be returned to normal and the subjects will be treated with intravenous glucose. An additional blood sample will be collected for laboratory determination of glucose and hormone concentrations 15 minutes following the treatment with intravenous glucose. Subjects will then be given breakfast and discharged. Prior to discharge, the sensor(s) will be removed and downloaded. The subject's insulin pump will be downloaded if possible.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Type 1 Diabetes
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.
2. Age 3.0 to \<7.0 years or 12.0 to \<18.0 years
3. Weight \>12.8 kg (28.2 lbs) for reinfusion centers (centers that employ reinfusion of blood drawn to clear the dead space in intravenous catheters) and \>17.4 kg (38.3 lbs) for discard centers (centers that discard the blood drawn to clear the dead space)
4. Hemoglobin A1c \<10.0%
5. Subject currently uses an insulin pump
6. Parent/guardian and subject understand the study protocol and agree to comply with it
7. Informed Consent Form signed by the parent/guardian and Child Assent Form signed by the subject
2. Age 3.0 to \<7.0 years or 12.0 to \<18.0 years
3. Weight \>12.8 kg (28.2 lbs) for reinfusion centers (centers that employ reinfusion of blood drawn to clear the dead space in intravenous catheters) and \>17.4 kg (38.3 lbs) for discard centers (centers that discard the blood drawn to clear the dead space)
4. Hemoglobin A1c \<10.0%
5. Subject currently uses an insulin pump
6. Parent/guardian and subject understand the study protocol and agree to comply with it
7. Informed Consent Form signed by the parent/guardian and Child Assent Form signed by the subject
Exclusion Criteria
1. The presence of a significant medical disorder or use of any medication that in the judgment of the investigator will affect the wearing of the sensors or the completion of any aspect of the protocol.
2. Adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment
3. A severe hypoglycemic event resulting in seizure or loss of consciousness in the last month
4. Use of systemic or inhaled corticosteroids in the last month
5. Cystic fibrosis
2. Adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment
3. A severe hypoglycemic event resulting in seizure or loss of consciousness in the last month
4. Use of systemic or inhaled corticosteroids in the last month
5. Cystic fibrosis
Minimum Eligible Age
3 Years
Maximum Eligible Age
17 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Sponsor Role
collaborator
Jaeb Center for Health Research
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roy W Beck, MD, PhD
Role: STUDY_DIRECTOR
Jaeb Center for Health Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Pediatric Endocrinology and Diabetes, Stanford University
Stanford, California, United States
Site Status
Barbara Davis Center for Childhood Diabetes, University of Colorado
Aurora, Colorado, United States
Site Status
Department of Pediatrics, Yale University School of Medicine
New Haven, Connecticut, United States
Site Status
Nemours Children's Clinic
Jacksonville, Florida, United States
Site Status
Jaeb Center for Health Research
Tampa, Florida, United States
Site Status
Department of Pediatrics, University of Iowa
Iowa City, Iowa, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Tsalikian E, Mauras N, Beck RW, Tamborlane WV, Janz KF, Chase HP, Wysocki T, Weinzimer SA, Buckingham BA, Kollman C, Xing D, Ruedy KJ; Diabetes Research In Children Network Direcnet Study Group. Impact of exercise on overnight glycemic control in children with type 1 diabetes mellitus. J Pediatr. 2005 Oct;147(4):528-34. doi: 10.1016/j.jpeds.2005.04.065.
Reference Type
BACKGROUND
Weinzimer SA, Beck RW, Chase HP, Fox LA, Buckingham BA, Tamborlane WV, Kollman C, Coffey J, Xing D, Ruedy KJ; Diabetes Research in Children Network Study Group. Accuracy of newer-generation home blood glucose meters in a Diabetes Research in Children Network (DirecNet) inpatient exercise study. Diabetes Technol Ther. 2005 Oct;7(5):675-80; discussion 681-3. doi: 10.1089/dia.2005.7.675.
Reference Type
BACKGROUND
Diabetes Research in Children Network (DirecNet) Study Group. Impaired overnight counterregulatory hormone responses to spontaneous hypoglycemia in children with type 1 diabetes. Pediatr Diabetes. 2007 Aug;8(4):199-205. doi: 10.1111/j.1399-5448.2007.00248.x.
Reference Type
BACKGROUND
Diabetes Research In Children Network (Direcnet) Study Group; Buckingham BA, Kollman C, Beck R, Kalajian A, Fiallo-Scharer R, Tansey MJ, Fox LA, Wilson DM, Weinzimer SA, Ruedy KJ, Tamborlane WV. Evaluation of factors affecting CGMS calibration. Diabetes Technol Ther. 2006 Jun;8(3):318-25. doi: 10.1089/dia.2006.8.318.
Reference Type
BACKGROUND
Tansey MJ, Tsalikian E, Beck RW, Mauras N, Buckingham BA, Weinzimer SA, Janz KF, Kollman C, Xing D, Ruedy KJ, Steffes MW, Borland TM, Singh RJ, Tamborlane WV; Diabetes Research in Children Network (DirecNet) Study Group. The effects of aerobic exercise on glucose and counterregulatory hormone concentrations in children with type 1 diabetes. Diabetes Care. 2006 Jan;29(1):20-5. doi: 10.2337/diacare.29.1.20.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DirecNet 009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Continuous Glucose Monitoring in Infants
NCT04458649
RECRUITING
Continuous Glucose Monitoring and Hypoglycemia Unawareness in Type 1 Diabetes
NCT03605979
COMPLETED
Randomized Study of Real-Time Continuous Glucose Monitors (RT-CGM) in the Management of Type 1 Diabetes
NCT00406133
COMPLETED
PHASE3
Diabetes Self-management With Continuous Glucose Monitoring
NCT06453434
NOT_YET_RECRUITING
Use of Continuous Glucose Monitoring System With Intensive Feedback in Adolescents With Poorly Controlled Type 1 Diabetes
NCT03020069
COMPLETED
NA
Feasibility and Effectiveness of Real-time, Remote Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes
NCT04540536
COMPLETED
NA
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
NCT05973799
RECRUITING
NA
Using Wearable Sensors To Understand Low Blood Sugar in Type 1 Diabetes
NCT06727071
NOT_YET_RECRUITING
NA
Continuous Glucose Monitor in Children With Poorly Controlled Diabetes
NCT02530450
COMPLETED
Reversal of Hypoglycemia Unawareness Using Continuous Glucose Monitoring
NCT00796848
WITHDRAWN
NA
Effect of Continuous Glucose Monitoring on Course of Glucose in Type 1 Diabetes
NCT00467688
COMPLETED
NA
Beta Cell Function in (Pre)Type 1 Diabetes
NCT01402037
UNKNOWN
NA
Preschool CGM Use and Glucose Variability in Type 1 Diabetes
NCT03293082
COMPLETED
Hypo-METRICS: Hypoglycaemia - Measurement, ThResholds and ImpaCtS
NCT04304963
COMPLETED
EEG-Changes During Insulininduced Hypoglycemia in Type 1 Diabetes
NCT00810420
COMPLETED
Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes
NCT02734667
COMPLETED
NA
Severe Hypoglycemia in Pregnant Women With Type 1 Diabetes
NCT00435565
COMPLETED
Accuracy of Continuous Glucose Monitors During the Perioperative Period in Youth With Type 1 Diabetes
NCT06575842
RECRUITING
The Effect of Frequent Continuous Glucose Monitoring Use on Glucose Variability in Preschoolers With Type 1 Diabetes
NCT04558710
COMPLETED
Randomized Clinical Trial to Assess the Effectiveness of the GlucoWatch Biographer
NCT00069628
COMPLETED
PHASE4
Telemedicine Monitoring of Nocturnal Incidents
NCT04328896
COMPLETED
NA
Efficacy of Continuous Glucose Monitoring in Neonates With Hypoglycemia
NCT02300285
TERMINATED
NA
Incidence of Hypoglycaemia Events in Patients With Stable Insulin-treated Type 2 Diabetes Mellitus Based on Continuous Glucose Monitoring
NCT05461716
UNKNOWN
Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 1 Diabetes at High Risk for Low Glucose Values Using Multiple Daily Injections (MDI) in Germany (HYPODE-STUDY)
NCT02671968
COMPLETED
NA
Continuous Glucose Monitoring in New Mothers With Type 1 Diabetes
NCT02898428
COMPLETED